Janney Healthcare Group Participates in Transactions for PLx Pharma


PLx Pharma Inc. (NASDAQ:PLXP), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg, announced that it has entered into a Securities Purchase Agreement with certain investors providing for the issuance of 2,646,091 shares of common stock at an offering price per share of $6.875 in a registered direct offering, and also agreed to issue unregistered warrants to the investors in a concurrent private placement to purchase up to an equivalent number of shares of common stock with an exercise price of $7.50 per share, resulting in expected gross proceeds to the Company of approximately $18.2 million.

Janney Montgomery Scott served as the co-lead placement agent on this offering.

April 19, 2017 - PLx Pharma Inc. has completed its previously announced merger with Dipexium Pharmaceuticals, Inc. ("Dipexium"). The combined company, which changed its name to PLx Pharma Inc. immediately following the merger, will begin trading on the NASDAQ Capital Market under the symbol "PLXP" on April 20, 2017.

Janney Montgomery Scott served as exclusive financial advisor to PLx Pharma on this transaction.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.